BioIntelliSense

BioIntelliSense is a passive remote patient monitoring company offering a medical-grade Data-as-a-Service (DaaS) platform that captures multi-parameter vital signs and physiological biometrics for chronic care management and early disease detection. Its key offering is the BioButton, a disposable wearable device that continuously captures the vital signs of patients for 30 days. The company claims it is an industry-first multi-parameter wearable device for remote patient monitoring that is capable of transmitting up to 1,440 vital signs per day.

The company’s continuous monitoring solutions are used both in-hospital and for remote monitoring in therapeutic areas such as oncology, orthopedic, maternal health, and complex care. It operates a B2B2C business model, partnering with several healthcare providers. 

In October 2022, the company acquired patient monitoring platform AlertWatch for an undisclosed sum to expand it’s remote patient monitoring offerings by incorporating AlertWatch into its BioButton remote patient wearable. 

Key customers and partnerships

The company has several collaborations to scale the development of its devices including UCHealth and CARE Innovation Center. In November 2022, the company partnered with the Translational Research Institute to study human health in space using the BioButton. 

The company has also established several key customers to expand its products; these include partnerships with 1) Mubadala Health to expand its offerings to healthcare providers in the UAE (March 2022), 2) UC Davis Health and Houston Methodist to deploy its platform at the center (May 2022/November 2023), 3)Medtronic plc to provide Medtronic an exclusive license to distribute Biobutton to US hospitals via its remote patient monitoring solutions (August 2022), 4) Ardent Health Services to use the BioButton across Ardent’s 30 hospitals for remote monitoring (November 2022), and 5) care.ai to integrate their technologies in optimizing clinical operations at healthcare facilities (January 2023).

Funding and financials

The company raised USD 45 million in July 2021 in an oversubscribed Series B funding round led by Chimera (UAE). The funds were directed toward scaling its digital health and clinical intelligence platform as well as to globally expand its wearable devices and data services for remote patient care.